Rexahn Pharmaceuticals Inc.


Rexahn Pharmaceuticals, Inc. (RNN) Phase 2a Update in Muscle Invasive Bladder Cancer Shows Promise, Cheers H.C. Wainwright

RNN’s Phase 2a results have analyst optimistic on RX-3117 drug for patients running out of options.

Rexahn Pharmaceuticals, Inc. (RNN): Chang Ahn Stepping Down

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) announced its founder, Chang Ahn, Ph.

Rexahn Pharmaceuticals, Inc. (RNN) Strengthens Patent Portfolio Through Newly Issued Patent for Cancer Drug Supinoxin

Rexahn Strengthens Patent Portfolio Through Newly Issued Patent for Cancer Drug

Rexahn Pharmaceuticals, Inc. (RNN) Announces 2Q:17 Financial and Operational Results

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) announced financial results for the second quarter ended June 30, 2017 and provided an update on the Company’s clinical …

Rexahn Pharmaceuticals, Inc. (RNN) Tumbles on Share Dilution

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) announced it has entered into definitive agreements with institutional investors to purchase approximately 3.

Rodman & Renshaw Encouraged on Rexahn Pharmaceuticals, Inc. (RNN) Following ASCO Update

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) offered a key glimpse into its advanced muscle invasive bladder cancer (MIBC) Phase 2a trial ¬†at the American Society …

Rexahn Pharmaceuticals, Inc. (RNN) Challenged with Financing Overhang; FBR Slashed Price Target

FBR analyst Vernon Bernardino, one of Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) biggest bulls, is slashing the price target for the drug maker to $14.

Rexahn Pharmaceuticals, Inc. (RNN) Announces Q1:17 Results

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) announced financial results for the first quarter ended March 31, 2017 and provided an update on the Company’s clinical …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts